Adbry® Autoinjector Now Available for Adults with Moderate-to-Severe Atopic Dermatitis in the U.S.

LEO Pharma Inc. has introduced a new tralokinumab-ldrm product, Adbry, in the United States. This product, aimed at individuals aged 12 and older with moderate-to-severe atopic dermatitis (AD), is now available in a 300 mg/2 mL single-dose autoinjector. The new autoinjector is a significant advancement for patients whose AD is not effectively managed with topical treatments or for whom these treatments are unsuitable.

Previously, Adbry was available only in a 150 mg/1 mL pre-filled syringe. The introduction of the 300 mg/2 mL autoinjector offers a more convenient option for adult patients, reducing the number of injections needed by half compared to the pre-filled syringe. This new device aims to ease the burden of treatment for those living with the condition.

Jonathan Silverberg, M.D., Ph.D., a Professor of Dermatology at George Washington University, highlighted the importance of convenience in managing AD, stating that the new autoinjector reduces the number of injections and offers an additional management option for patients.

Despite the new autoinjector's availability, the pre-filled syringe will remain an option for both adult and pediatric patients (ages 12-17) in the U.S. Brian Hilberdink, EVP and President for Region North America at LEO Pharma, expressed pride in expanding administration options for Adbry, emphasizing the company's commitment to improving care standards for individuals with skin diseases and ongoing innovation in treatment options.

In the U.S., Adbry can be administered using either the 150 mg/1 mL pre-filled syringe or the new 300 mg/2 mL autoinjector. For adults, the treatment begins with an initial loading dose of 600 mg (four injections with the pre-filled syringe or two with the autoinjector), followed by a maintenance dose of 300 mg every two weeks. Patients achieving clear or nearly clear skin after 16 weeks, and weighing under 220 pounds, have the option to switch to a single 300 mg/2 mL dose every four weeks.

Outside the U.S., Adbry is marketed under the name Adtralza (tralokinumab) and is approved for treating both adults and pediatric patients (aged 12 and older) with moderate-to-severe AD in various regions, including Canada, the European Union, and South Korea. In Switzerland and Japan, Adtralza is approved for adult use.

Atopic dermatitis is a chronic skin condition marked by severe itching and eczematous lesions, resulting from skin barrier dysfunction and immune dysregulation. Type 2 cytokines like IL-13 play a pivotal role in the disease's pathophysiology. Adbry is a fully human monoclonal antibody designed to bind to and inhibit the IL-13 cytokine, which is involved in the inflammatory processes of AD. By targeting IL-13, Adbry prevents its interaction with specific receptor subunits, thereby mitigating the disease's symptoms.

LEO Pharma, founded in 1908 and headquartered in Denmark, is dedicated to advancing dermatological care. The company has a long history of research and development in dermatology, providing a wide range of therapies for various skin conditions. With a global team of 4,200 employees, LEO Pharma serves millions of patients worldwide and reported net sales of DKK 11.4 billion in 2023.